Drug Interactions between bupropion and clopidogrel
This report displays the potential drug interactions for the following 2 drugs:
- bupropion
- clopidogrel
Interactions between your drugs
buPROPion clopidogrel
Applies to: bupropion and clopidogrel
MONITOR: Coadministration with clopidogrel may increase the plasma concentrations of bupropion. The proposed mechanism is clopidogrel inhibition of bupropion hydroxylation via CYP450 2B6. In 12 healthy male volunteers, administration of a single 150 mg dose of bupropion in combination with clopidogrel (75 mg orally once daily for 4 days) resulted in a 40% increase in bupropion peak plasma concentration (Cmax) and 60% increase in systemic exposure (AUC) compared to administration of bupropion alone. Additionally, the AUC of the hydroxybupropion metabolite decreased by 52% and the AUC ratio of hydroxybupropion to bupropion decreased by 68% with clopidogrel, while oral clearance decreased by 26%. The clinical consequence of increased bupropion plasma levels and changes in the bupropion to hydroxybupropion ratio are currently unknown.
MANAGEMENT: Caution is advised if bupropion is prescribed with clopidogrel. Pharmacologic response to bupropion should be monitored closely whenever clopidogrel is added to or withdrawn from therapy. Based on clinical response, dose adjustments of bupropion may be necessary. Concomitant use with once-daily bupropion hydrochloride 450 mg extended release tablets is not recommended. When bupropion/naltrexone is used for weight loss, some authorities recommend a maximum bupropion dosage of 180 mg per day provided as 1 tablet (bupropion 90 mg/naltrexone 8 mg) twice a day (AU, CA, US). Patients should be advised to contact their physician if they experience symptoms of bupropion toxicity such as agitation, anxiety, tremor, insomnia and seizures, or neuropsychiatric symptoms such as delusions, hallucinations, psychosis, impaired concentration, paranoia and confusion.
References (11)
- (2001) "Product Information. Wellbutrin SR (bupropion)." Glaxo Wellcome
- (2001) "Product Information. Zyban (bupropion)." Glaxo Wellcome
- (2003) "Product Information. Wellbutrin XL (bupropion)." GlaxoSmithKline
- Richter T, Muerdter TE, Heinkele G, et al. (2004) "Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine." J Pharmacol Exp Ther, 308, p. 189-97
- Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K (2005) "Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation." Clin Pharmacol Ther, 77, p. 553-9
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2009) "Product Information. Aplenzin (bupropion)." sanofi-aventis
- (2014) "Product Information. Contrave (bupropion-naltrexone)." Orexigen Therapeutics Inc
- Cerner Multum, Inc. (2015) "Canadian Product Information."
- (2022) "Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc
Drug and food interactions
buPROPion food
Applies to: bupropion
GENERALLY AVOID: Excessive use or abrupt discontinuation of alcohol after chronic ingestion may precipitate seizures in patients receiving bupropion. Additionally, there have been rare postmarketing reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who drank alcohol during treatment with bupropion. According to one forensic report, a patient died after taking large doses of both bupropion and alcohol. It is uncertain whether a drug interaction was involved. Single-dose studies in healthy volunteers given bupropion and alcohol failed to demonstrate either a significant pharmacokinetic or pharmacodynamic interaction.
MANAGEMENT: The manufacturer recommends that alcohol consumption be minimized or avoided during bupropion treatment. The use of bupropion is contraindicated in patients undergoing abrupt discontinuation of alcohol.
References (4)
- Posner J, Bye A, Jeal S, Peck AW, Whiteman P (1984) "Alcohol and bupropion pharmacokinetics in healthy male volunteers." Eur J Clin Pharmacol, 26, p. 627-30
- Ramcharitar V, Levine BS, Goldberger BA, Caplan YH (1992) "Bupropion and alcohol fatal intoxication: case report." Forensic Sci Int, 56, p. 151-6
- Hamilton MJ, Bush MS, Peck AW (1984) "The effect of bupropion, a new antidepressant drug, and alcohol and their interaction in man." Eur J Clin Pharmacol, 27, p. 75-80
- (2001) "Product Information. Wellbutrin (bupropion)." Glaxo Wellcome
buPROPion food
Applies to: bupropion
MONITOR: Additive or synergistic effects on blood pressure may occur when bupropion is combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. Treatment with bupropion can result in elevated blood pressure and hypertension. In clinical practice, hypertension, in some cases severe and requiring acute treatment, has been observed in patients receiving bupropion alone and in combination with nicotine replacement therapy. These events have occurred in both patients with and without evidence of preexisting hypertension. Furthermore, postmarketing cases of hypertensive crisis have been reported during the initial titration phase with bupropion-naltrexone treatment.
MANAGEMENT: Caution is advised when bupropion is used with other drugs that increase dopaminergic or noradrenergic activity due to an increased risk of hypertension. Blood pressure and heart rate should be measured prior to initiating bupropion therapy and monitored at regular intervals consistent with usual clinical practice, particularly in patients with preexisting hypertension. Dose reduction or discontinuation of bupropion should be considered in patients who experience clinically significant and sustained increases in blood pressure or heart rate.
References (4)
- (2022) "Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc., 1
- (2022) "Product Information. Zyban (bupropion)." GlaxoSmithKline UK Ltd
- (2022) "Product Information. Wellbutrin XL (bupropion)." Bausch Health, Canada Inc.
- (2021) "Product Information. Contrave (bupropion-naltrexone)." Currax Pharmaceuticals LLC
buPROPion food
Applies to: bupropion
MONITOR: The concomitant use of bupropion and nicotine replacement for smoking cessation may increase the risk of hypertension. In a clinical study (n=250), 6.1% of patients who used sustained-release bupropion with nicotine transdermal system developed treatment-emergent hypertension, compared to 2.5% of patients treated with bupropion alone, 1.6% treated with nicotine alone, and 3.1% treated with placebo. Three patients in the bupropion plus nicotine group and one patient in the nicotine-only group discontinued treatment due to hypertension. The majority had evidence of preexisting hypertension.
MANAGEMENT: Blood pressure monitoring is recommended for patients concomitantly using bupropion and nicotine replacement for smoking cessation.
References (1)
- (2001) "Product Information. Zyban (bupropion)." Glaxo Wellcome
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.